Predictive Biomarkers for Immunotherapy Response in Extensive-stage SCLC

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Jan 20

PMID 38245636

Authors

Lin Zhu

Jing Qin

Affiliations

Soon will be listed here.

Abstract

Background: Small cell lung cancer (SCLC) accounts for about 13-15% of all lung cancers, and about 70% of SCLC patients have developed extensive-stage small cell lung cancer (ES-SCLC) at the time of diagnosis because of its highgrade malignancy, easy invasion, and metastasis. In recent years, immunotherapy combined with chemotherapy has become the standard first-line treatment for ES-SCLC. However, SCLC is a relatively immune-cold lung cancer subtype with a limited number of beneficiaries and a short benefit period. Therefore, the use of biomarkers to identify populations with significant benefits from immunotherapy will help improve the efficacy and survival benefits of immunotherapy. However, predictive biomarkers suitable for clinical practice have not been established in the field of SCLC.

Purpose: In order to find the predictive biomarkers of immunotherapy for ES-SCLC, we summarized the research progress of traditional biomarkers, such as programmed cell death ligand 1 (PD-L1) and tumor mutation burden (TMB), and summarizes the research of potential biomarkers associated with prognosis, such as molecular subtypes, special gene expression, expression of major histocompatibility complex (MHC) I and II classes, tumor immune microenvironment (TIME), and circulating tumor DNA (ctDNA) .We aim to provide new insights on biomarkers.

Conclusion: The exploration of biomarkers for immunotherapy of SCLC is still very difficult, and it is clear that conventional predictive biomarkers are not suitable for SCLC. At present, the molecular subtypes defined from transcription factors may have some guiding significance, which still needs to be confirmed by prospective clinical studies. In addition, the ctDNA positivity rate of SCLC is higher than that of other tumor types, which can also solve the dilemma of the difficulty of obtaining specimens of SCLC tissues. And the dynamic change of ctDNA also has great potential to predict the curative effect of SCLC, which is worth further clinical exploration.

Citing Articles

The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer.

Inanez A, Del Rey-Vergara R, Quimis F, Rocha P, Galindo M, Menendez S Int J Mol Sci. 2025; 26(3).

PMID: 39941061 PMC: 11818609. DOI: 10.3390/ijms26031293.

Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer.

Ouyang W, Xu Z, Guan S, Hu Y, Gou X, Liu Z Int J Biol Sci. 2025; 21(3):1322-1341.

PMID: 39897044 PMC: 11781172. DOI: 10.7150/ijbs.105973.

Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.

Wang B, Zhang J, Shi Y, Wang Y BMC Cancer. 2024; 24(1):1574.

PMID: 39719567 PMC: 11667841. DOI: 10.1186/s12885-024-13343-x.

LINC01089 in cancer: multifunctional roles and therapeutic implications.

Yi Q, Zhu G, Ouyang X, Zhu W, Zhong K, Chen Z J Transl Med. 2024; 22(1):858.

PMID: 39334363 PMC: 11429488. DOI: 10.1186/s12967-024-05693-8.

Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy.

Herranz-Bayo E, Chara-Velarde L, Cassinello-Espinosa J, Gimeno-Ballester V, Artal-Cortes A, Moratiel-Pellitero A Clin Transl Oncol. 2024; .

PMID: 39240302 DOI: 10.1007/s12094-024-03690-3.

References

Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G . Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022; 7(2):100408. PMC: 9161394. DOI: 10.1016/j.esmoop.2022.100408. View

Pellini B, Chaudhuri A . ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?. Clin Cancer Res. 2023; 29(12):2176-2178. PMC: 10330146. DOI: 10.1158/1078-0432.CCR-23-0420. View

Rudin C, Poirier J, Byers L, Dive C, Dowlati A, George J . Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019; 19(5):289-297. PMC: 6538259. DOI: 10.1038/s41568-019-0133-9. View

Zhang J, Zhang H, Zhang L, Li D, Qi M, Zhang L . Single-Cell Transcriptome Identifies Drug-Resistance Signature and Immunosuppressive Microenvironment in Metastatic Small Cell Lung Cancer. Adv Genet (Hoboken). 2023; 3(2):2100060. PMC: 9744506. DOI: 10.1002/ggn2.202100060. View

Rudin C, Awad M, Navarro A, Gottfried M, Peters S, Csoszi T . Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21):2369-2379. PMC: 7474472. DOI: 10.1200/JCO.20.00793. View

Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View

Ireland A, Micinski A, Kastner D, Guo B, Wait S, Spainhower K . MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell. 2020; 38(1):60-78.e12. PMC: 7393942. DOI: 10.1016/j.ccell.2020.05.001. View

Roper N, Velez M, Chiappori A, Kim Y, Wei J, Sindiri S . Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nat Commun. 2021; 12(1):3880. PMC: 8222224. DOI: 10.1038/s41467-021-24164-y. View

Nguyen E, Taniguchi H, Chan J, Zhan Y, Chen X, Qiu J . Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. J Thorac Oncol. 2022; 17(8):1014-1031. PMC: 9357096. DOI: 10.1016/j.jtho.2022.05.014. View

10.

Hellmann M, Callahan M, Awad M, Calvo E, Ascierto P, Atmaca A . Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):853-861.e4. PMC: 6750707. DOI: 10.1016/j.ccell.2018.04.001. View

11.

Vautrot V, Bentayeb H, Causse S, Garrido C, Gobbo J . Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. Cancers (Basel). 2021; 13(18). PMC: 8467727. DOI: 10.3390/cancers13184537. View

12.

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

13.

Tang Y, Hu Y, Niu Y, Sun L, Guo L . CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer. Front Med (Lausanne). 2022; 9:834725. PMC: 8891515. DOI: 10.3389/fmed.2022.834725. View

14.

Cao Y, Ma Y, Yu J, Sun Y, Sun T, Shao Y . Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Commun (Lond). 2020; 40(12):746-751. PMC: 7743014. DOI: 10.1002/cac2.12114. View

15.

Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M . Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discov. 2022; 12(7):1656-1675. PMC: 9394384. DOI: 10.1158/2159-8290.CD-21-1434. View

16.

Chen Y, Fang Z, Tang Y, Jin Y, Guo C, Hu L . Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer. Clin Transl Med. 2021; 11(12):e620. PMC: 8684774. DOI: 10.1002/ctm2.620. View

17.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

18.

Ott P, Bang Y, Piha-Paul S, Abdul Razak A, Bennouna J, Soria J . T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2018; 37(4):318-327. DOI: 10.1200/JCO.2018.78.2276. View

19.

Tian Y, Zhai X, Han A, Zhu H, Yu J . Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 2019; 12(1):67. PMC: 6599302. DOI: 10.1186/s13045-019-0753-2. View

20.

Zhu Y, Wu S . [Immune Characteristics of Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2020; 23(10):889-896. PMC: 7583879. DOI: 10.3779/j.issn.1009-3419.2020.101.33. View